IMCI is a pharmaceutical company that develops innovative pharma-grade and formulated cannabis-based medications to treat chronic indications with a global reach.
 

IMCI has developed a precise and effective dose together with an easy-to-use administration, suitable for any patient population at any time and place via its iCann medicinal cannabis platform.

​

IMCI research and development is based on an Israeli leading academic research institution in collaboration with established Israeli pharmaceutical providers which together with its team members, possess a proven track record in developing innovative cannabis-based medications.

​